It’s Bittersweet: The Tumorigenic Potential of Glycosylation

Event Overview

Early cancer detection is a key determinant of patient survival, but scientists struggle to identify reliable biomarkers and diagnostic tools. Researchers recently discovered cancer-specific glycosylation signatures that promote tumor progression. Because protein glycosylation controls cellular behaviors such as cell adhesion and migration, altered glycosylation states render cancer cells more invasive. In this webinar, brought to you by Vector Laboratories, Karen Abbott and Susan Bellis will discuss how cancer cells modify glycosylation pathways to survive, and how to target tumor-specific glycans for early cancer detection, prognosis, and therapeutic development.

Topics to be covered

  • Tools and technologies to detect glycan biomarkers
  • How cancer-induced receptor glycosylation activates tumorigenic pathways
  • The therapeutic potential of tumor-selective glycans

  • Monday, December 6, 2021
    3:00 - 4:30 PM Eastern Time

    Meet the speakers

    Karen Abbott, PhD
    Associate Professor
    Department of Translational Medicine
    Herbert Wertheim College of Medicine
    Florida International University

    Susan L. Bellis, PhD
    Department of Cell, Developmental, and Integrative Biology
    University of Alabama at Birmingham

    Sponsored by



    TS_WEBINAR_Vector Labs Labtools_December 6, 2021

    You must have Javascript and Cookies enabled to access this webcast.

    Information you provide will be shared with the sponsors for this content. The Scientist or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.